News and Trends 13 Jun 2022 GSK positive on RSV vaccine for older adults …and longer-term protection over multiple seasons following one dose of the RSV older adult vaccine candidate. GSK’s RSV older adult vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein… June 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2023 The big pharma race against deadly RSV steps up in 2023 …vaccine candidate to the market soon. It submitted an application for regulatory approval as well as a Biologics License Application in July. Its investigational candidate MRNA-1345, consists of a single… December 21, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 May 2023 Six Norwegian companies leading the country’s biotech scene …two candidates focused on treating indications including cancer and respiratory diseases. Its lead drug candidate is bemcentinib, which is being investigated as a therapy against acute myeloid leukemia, non-small cell… May 17, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2025 3 promising biotech approaches to treat Hunter syndrome, a rare genetic disorder …are pursuing different methods of tackling the disease, with several candidates in clinical trials that are showing promise. In this article, we explore the three main technology approaches for treating… February 20, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Oct 2024 Six biotechs driving progress in Duchenne muscular dystrophy …dystrophin protein. The trial results showed that the candidate had a 5.5% mean absolute unadjusted dystrophin in patients after 24 weeks. Wave also reported mean absolute muscle content-adjusted dystrophin expression… October 3, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2025 AstraZeneca bets on Asia: a surge of deals in March amid fraud probe …BioMed to gain an option to license multiple programs derived from the latter’s Harbour Mice fully human antibody technology platform. The platform creates heavy chain antibodies – around half the… March 31, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration… September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 von Willebrand disease treatment gets FDA orphan drug designation The U.S. Food and Drug Administration (FDA) has granted Vega Therapeutics, Inc. orphan drug designation for its antibody therapy, VGA039, for the treatment of the rare bleeding disorder, von Willebrand… June 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced… June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe …3-10% or more than 10% of the body is affected. Guselkumab (Tremfya) is a human anti-IL-23 monoclonal antibody developed by Janssen and generated using MorphoSys’s Human Combinatorial Antibody Library (HuCAL)… November 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Integral Molecular joins FDA’s ISTAND program …by allowing them to be used in regulatory (IND, NDA or BLA) applications without needing the FDA to reconsider and reconfirm their suitability. Integral Molecular said antibodies and antibody-based therapies,… September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Astellas developing new gastric cancer drug …antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first… June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email